A double-blind, multi-centre controlled trial of 0.25% oxymetazoline ophthalmic solution in patients with allergic and non-infectious conjunctivitis.
Oxymetazoline (0.025%) ophthalmic solution, 2 drops 4-times daily, was compared with a placebo in the treatment of allergic and non-infectious conjunctivitis. In this 1 week, double-blind, multi-centre study, oxymetazoline proved significantly superior to the placebo (p < 0.001) in providing rapid and sustained clearing of inflamed conjunctiva. Overall, 84% of allergic patients treated with oxymetzoline were improved compared to 58% on placebo. Patients with non-infectious conjunctivitis exhibited a high degree of improvement (94%) compared to placebo (51%).
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D003231:Conjunctivitis / Q000188:drug therapy* / Q000209:etiology; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000150:complications / Q000188:drug therapy; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010109:Oxymetazoline / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D011897:Random Allocation
D007093:Imidazoles; D010919:Placebos; D010109:Oxymetazoline